-

Abcuro Appoints Sarah Boyce to its Board of Directors

NEWTON, Mass.--(BUSINESS WIRE)--Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced the appointment of Sarah Boyce to its Board of Directors. Ms. Boyce brings more than 25 years of global commercial leadership experience in the life sciences industry.

“We are excited to welcome Sarah as a member of the Board and her experience will be instrumental as we focus on advancing ulviprubart in the ongoing Phase 3 MUSCLE trial for the treatment of inclusion body myositis,” said Mark Pruzanski, M.D., Chairman of the Board of Directors. “Sarah has extensive expertise in global product development, rare diseases and commercialization having helped bring over 20 products to market.”

Ms. Boyce currently serves as the President and Chief Executive Officer of Avidity Biosciences, a publicly traded biotechnology company developing novel therapies for muscle wasting and other rare diseases. Prior to Avidity, she was President of Akcea Therapeutics and previously in her career held executive roles in business development and global operations for leading life sciences companies, including Ionis Pharmaceuticals, Forest Laboratories, Alexion Pharmaceuticals, Novartis Oncology and F. Hoffmann-La Roche AG. Ms. Boyce was named a Healthcare Technology Report Top 25 Biotech CEO in 2022 and one of the Fiercest Women in Life Sciences. She currently serves as a member of the Board of Directors at OmniAb and Contineum Therapeutics. Ms. Boyce holds a BSc (Hons) degree in microbiology from the University of Manchester, England.

“I am thrilled to join Abcuro’s board at this critical point in the Company’s journey,” said Ms. Boyce. “I look forward to collaborating with the management team, providing guidance and sharing my expertise as the company progresses towards potential regulatory approval and readiness for potential commercialization.”

About Abcuro

Abcuro is a clinical stage biotechnology company developing first-in-class immunotherapies for the treatment of autoimmune diseases and cancer through precise modulation of highly cytotoxic T cells. The company’s lead program is ulviprubart (ABC008) and is currently in clinical trials for inclusion body myositis (IBM) and T cell large granular lymphocytic leukemia.

For more information, visit us on LinkedIn and at abcuro.com.

Contacts

Matthew DeYoung
Investor Relations and Media
Argot Partners
abcuro@argotpartners.com

Industry:

Abcuro, Inc.

Release Versions
English

Contacts

Matthew DeYoung
Investor Relations and Media
Argot Partners
abcuro@argotpartners.com

More News From Abcuro, Inc.

Abcuro Announces Topline Results from the MUSCLE Study of Ulviprubart in Patients with Inclusion Body Myositis

NEWTON, Mass.--(BUSINESS WIRE)--Abcuro, Inc., today announced topline results from the Phase 2/3 MUSCLE clinical study of ulviprubart (ABC008), an investigational monoclonal antibody in development for the treatment of patients with inclusion body myositis (IBM), a rare, debilitating and relentlessly progressive chronic autoimmune disease that currently has no approved treatment options. The MUSCLE study did not meet its primary endpoint, assessed by the IBM Functional Rating Scale (IBMFRS) tot...

Abcuro Presents Interim Phase 1 Data Evaluating Ulviprubart in Patients with T Cell Large Granular Lymphocytic Leukemia at the 67th American Society of Hematology Annual Meeting

NEWTON, Mass.--(BUSINESS WIRE)--Abcuro, Inc., a late-stage clinical biotechnology company developing potentially first-in-class immunotherapies designed to benefit people living with debilitating and progressive rare autoimmune diseases and for other indications where certain cytotoxic T cells are pathogenic, today presented interim data from the ongoing Phase 1/2 clinical trial evaluating ulviprubart (ABC008) in patients with T cell large granular lymphocytic leukemia (T-LGLL) with anemia and/...

Abcuro to Present Interim Phase 1 Data Evaluating Ulviprubart in Patients with T Cell Large Granular Lymphocytic Leukemia at the 67th American Society of Hematology Annual Meeting

NEWTON, Mass.--(BUSINESS WIRE)--Abcuro, Inc., a late-stage clinical biotechnology company developing potential first-in-class immunotherapies for the benefit of people living with debilitating and progressive rare autoimmune diseases and cancers, today announced that the Company will present interim data from the Phase 1/2 clinical trial evaluating the safety, tolerability, and hematological effect of ulviprubart in patients with T cell large granular lymphocytic leukemia (T-LGLL) who suffer fr...
Back to Newsroom